Ovarian cancer update: Lessons from morphology, molecules, and mice

Archives of Pathology and Laboratory Medicine

Volumn 133, Issue 11, 2009, Pages 1775-1781

  Cho, Kathleen R ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER THERAPY; CONFERENCE PAPER; ENDOMETRIUM CARCINOMA; GENE EXPRESSION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; NONHUMAN; OVARY CARCINOMA; OVARY TUMOR;

ADENOCARCINOMA; ADENOCARCINOMA, CLEAR CELL; ADENOCARCINOMA, MUCINOUS; ANIMALS; CARCINOMA, ENDOMETRIOID; CYSTADENOCARCINOMA, SEROUS; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HUMANS; MICE; MUTATION; OVARIAN NEOPLASMS;

EID: 70449338171     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (34)

1. Markman M. Pharmaceutical management of ovarian cancer: current status. Drugs. 2008;68(6):771-789. (Pubitemid 351550530)
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Ver 1. Fort Washington, Pennsylvania: NCCN; 2006.
3. Cho KR, Shih IM. Ovarian cancer. Annu Rev Pathol Mech Dis. 2009;4(1): 287-313.
4. Sanseverino F, D'Andrilli G, Petraglia F, Giordano A. Molecular pathology of ovarian cancer. Anal Quant Cytol Histol. 2005;27(3):121-124.
5. Bell DA. Origins and molecular pathology of ovarian cancer. Mod Pathol. 2005;18(suppl 2):S19-S32. (Pubitemid 40188615)
6. Singer G, Stöhr R, Cope L, et al. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol. 2005;29(2):218-224. (Pubitemid 40170640)
7. Salani R, Kurman RJ, Giuntoli R II, et al. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance. Int J Gynecol Cancer. 2008;18(3):487-491. (Pubitemid 351668307)
8. Enomoto T, Weghorst CM, Inoue M, Tanizawa O, Rice JM. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol. 1991;139(4):777-785.
9. Gemignani ML, Schlaerth AC, Bogomolniy F, et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol. 2003;90(2): 378-381. (Pubitemid 36952030)
10. Wu R, Hendrix-Lucas N, Kuick R, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/β-catenin and PI3K/Pten signaling pathways. Cancer Cell. 2007;11(4):321-333. (Pubitemid 46518315)
11. Wright K, Wilson P, Morland S, et al. β-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int J Cancer. 1999;82(5):625-629. (Pubitemid 29356957)
12. Kuo KT, Mao TL, Jones S, et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. Am J Pathol. 2009;174(5):1597-1601.
13. Schwartz DR, Kardia SL, Shedden KA, et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 2002;62(16): 4722-4729.
14. Miller JR. The Wnts. Genome Biol. 2002;3(1):reviews3001. doi:10.1186/gb-2001-3-1-reviews3001.
15. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434(7035):843-850. (Pubitemid 40558990)
16. Dale TC. Signal transduction by the Wnt family of ligands. Biochem J. 1998;329(pt 2):209-223.
17. Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24(50):7455-7464. (Pubitemid 41637985)
18. Sansal I, Sellers WR. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol. 2004;22(14):2954-2963. (Pubitemid 41079915)
19. Kolasa IK, Rembiszewska A, Janiec-Jankowska A, et al. PTEN mutation, expression and LOH at its locus in ovarian carcinomas: relation to TP53, K-RAS and BRCA1 mutations. Gynecol Oncol. 2006;103(2):692-697. (Pubitemid 44602189)
20. Tomasini R, Mak TW, Melino G. The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol. 2008;18(5):244-252.
21. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 2007;26(15):2157-2165. (Pubitemid 46536647)
22. McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol. 2008;61(17):152-163.
23. Care A, Felicetti F, Meccia E, et al. HOXB7: a key factor for tumor-associated angiogenic switch. Cancer Res. 2001;61(17):6532-6539. (Pubitemid 32783261)
24. Singer G, Kurman RJ, Chang HW, Cho SK, Shih IeM. Diverse tumorigenic pathways in ovarian serous carcinoma. Am J Pathol. 2002;160(4): 1223-1228. (Pubitemid 34411626)
25. Smith-Sehdev AE, Sehdev PS, Kurman RJ. Noninvasive and invasive micropapillary (low-grade) serous carcinoma of the ovary: a clinicopathologic analysis of 135 cases. Am J Surg Pathol. 2003;27(6):725-736.
26. Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol. 2004;164(5):1511- 1518.
27. Shih IeM, Kurman RJ. Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges. Clin Cancer Res. 2005;11(20):7273-7279.
28. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211(1):26-35. (Pubitemid 46092026)
29. Crum CP, Drapkin R, Miron A, et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007;19(1): 3-9. (Pubitemid 46095865)
30. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31(2):161-169. (Pubitemid 46175016)
31. Jacobs IJ, Skates SJ, MacDonald N, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet. 1999;353(9160):1207-1210. (Pubitemid 29168457)
32. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248-1259.
33. Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28(4):496-504. (Pubitemid 38436523)
34. Seidman JD, Horkayne-Szakaly I, Cosin JA, et al. Testing of two binary grading systems for FIGO stage III serous carcinoma of the ovary and peritoneum. Gynecol Oncol. 2006;103(2):703-708. (Pubitemid 44602191)